Toru Miyazaki MD, PhD

Toru Miyazaki graduated from the University of Tokyo School of Medicine in 1986. Joined the Third Internal Medicine Department of the University of Tokyo Hospital. After completing studies at Kumamoto University Graduate School, worked as a researcher at the Louis Pasteur University of Strasbourg/IGBMC (France) from 1992, Principal Researcher at the Basel Institute for Immunology (Switzerland) from 1995, Associate Professor at Center for Immunology at the University of Texas Southwestern Medical Center at Dallas (USA) from 2000, and served as a professor at the Graduate School of Medicine, University of Tokyo, from 2006 to 2022.

Since April 2022, he has been the President and Director of the Institute for AIM Medicine (IAM). In 1999, he discovered AIM and subsequently advanced his research, promoting AIM drug development for various diseases including kidney disease. During this time, he discovered that AIM is congenitally dysfunctional in cats, leading to the development of AIM-based veterinary medicine targeting kidney disease in cats.